Table 1 Baseline and treatment characteristics according to subtype
TN | HER2+ | All | ||||
|---|---|---|---|---|---|---|
(n = 45) | (n = 60) | (n = 105) | ||||
n | (%) | n | (%) | n | (%) | |
Age (years) | ||||||
Median (IQR) | 50 | (36–55) | 45 | (37–52) | 47 | (37–54) |
Tumour size on MRI (mm) | ||||||
Median (IQR) | 31 | (22–45) | 38 | (22–60) | 33 | (22–50) |
Disease stage | ||||||
II | 19 | (42%) | 26 | (43%) | 45 | (43%) |
III | 26 | (58%) | 34 | (57%) | 60 | (57%) |
Baseline axillary staging method | ||||||
Positive, pre-SNPa | 1 | (2%) | 0 | (0%) | 1 | (1%) |
Positive, FNA | 44 | (98%) | 60 | (100%) | 104 | (99%) |
Grade | ||||||
1–2 | 13 | (29%) | 25 | (42%) | 38 | (36%) |
3 | 16 | (36%) | 14 | (23%) | 30 | (29%) |
Unknown | 16 | (36%) | 21 | (35%) | 37 | (35%) |
Histology | ||||||
Ductal | 43 | (96%) | 55 | (92%) | 98 | (93%) |
Lobular | 0 | (0%) | 4 | (7%) | 4 | (4%) |
Other | 2 | (4%) | 1 | (2%) | 3 | (3%) |
HR-status | ||||||
ER- and PR- | 45 | (100%) | 29 | (48%) | 74 | (71%) |
ER+ and/or PR+ | 0 | (0%) | 31 | (52%) | 31 | (30%) |
Treatment | ||||||
ACb | 45 | (100%) | 0 | (0%) | 45 | (43%) |
PTCc | 0 | (0%) | 60 | (100%) | 60 | (57%) |
PET assessment | ||||||
PET1 performed | 45 | (100%) | 60 | (100%) | 105 | (100%) |
PET2 performed | 35 | (78%) | 45 | (75%) | 80 | (76%) |
PET3 performed | 38 | (84%) | 47 | (78%) | 84 | (80%) |